Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.

Deng LW, Xie QY, Peng B, Zhao Y, Liu B, Feng SF, Liu DX, Sun YY, Wang HQ, Liao CL, Wang YL, Liu JF, Zhang C, Chen Y, Xu GH, Liu L, Cao L, Wei G, Ren Y, Yang XG

Open source

DOI: 10.1016/j.ejrad.2025.112401
Published: 2025 Nov
Container: European journal of radiology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejrad.2025.112401,
  title = {Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.},
  author = {Deng LW and Xie QY and Peng B and Zhao Y and Liu B and Feng SF and Liu DX and Sun YY and Wang HQ and Liao CL and Wang YL and Liu JF and Zhang C and Chen Y and Xu GH and Liu L and Cao L and Wei G and Ren Y and Yang XG},
  year = {2025},
  journal = {European journal of radiology},
  doi = {10.1016/j.ejrad.2025.112401},
  url = {https://doi.org/10.1016/j.ejrad.2025.112401}
}

RIS

TY  - JOUR
TI  - Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.
AU  - Deng LW
AU  - Xie QY
AU  - Peng B
AU  - Zhao Y
AU  - Liu B
AU  - Feng SF
AU  - Liu DX
AU  - Sun YY
AU  - Wang HQ
AU  - Liao CL
AU  - Wang YL
AU  - Liu JF
AU  - Zhang C
AU  - Chen Y
AU  - Xu GH
AU  - Liu L
AU  - Cao L
AU  - Wei G
AU  - Ren Y
AU  - Yang XG
PY  - 2025
JO  - European journal of radiology
DO  - 10.1016/j.ejrad.2025.112401
UR  - https://doi.org/10.1016/j.ejrad.2025.112401
ER  -

APA

LW, D., QY, X., B, P., Y, Z., B, L., SF, F., DX, L., YY, S., HQ, W., CL, L., YL, W., JF, L., C, Z., Y, C., GH, X., L, L., L, C., G, W., Y, R., & XG, Y. (2025). Predicting tumor response to TACE plus lenvatinib and PD-1 inhibitors for unresectable HCC: A multicenter observational study.. European journal of radiology. https://doi.org/10.1016/j.ejrad.2025.112401

Source records

pubmed · retrieved 2026-09-25T12:23:20.313Z
europe-pmc · retrieved 2026-09-25T12:23:20.336Z